CN112826917A - Compound mulberry and astragalus traditional Chinese medicine composition and application thereof - Google Patents
Compound mulberry and astragalus traditional Chinese medicine composition and application thereof Download PDFInfo
- Publication number
- CN112826917A CN112826917A CN202110249323.4A CN202110249323A CN112826917A CN 112826917 A CN112826917 A CN 112826917A CN 202110249323 A CN202110249323 A CN 202110249323A CN 112826917 A CN112826917 A CN 112826917A
- Authority
- CN
- China
- Prior art keywords
- parts
- chinese medicine
- traditional chinese
- astragalus
- mulberry
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000003814 drug Substances 0.000 title claims abstract description 91
- 235000008708 Morus alba Nutrition 0.000 title claims abstract description 37
- 240000000249 Morus alba Species 0.000 title claims abstract description 36
- 235000006533 astragalus Nutrition 0.000 title claims abstract description 33
- 239000000203 mixture Substances 0.000 title claims abstract description 26
- 150000001875 compounds Chemical class 0.000 title claims abstract description 19
- 241001061264 Astragalus Species 0.000 title claims abstract description 14
- 210000004233 talus Anatomy 0.000 title claims abstract description 14
- 201000005569 Gout Diseases 0.000 claims abstract description 40
- 229940079593 drug Drugs 0.000 claims abstract description 27
- 108010028690 Fish Proteins Proteins 0.000 claims abstract description 24
- 241000045403 Astragalus propinquus Species 0.000 claims abstract description 19
- 235000007542 Cichorium intybus Nutrition 0.000 claims abstract description 19
- 201000001431 Hyperuricemia Diseases 0.000 claims abstract description 18
- 241000234435 Lilium Species 0.000 claims abstract description 17
- 244000197580 Poria cocos Species 0.000 claims abstract description 17
- 235000008599 Poria cocos Nutrition 0.000 claims abstract description 17
- 244000303040 Glycyrrhiza glabra Species 0.000 claims abstract description 16
- 235000006200 Glycyrrhiza glabra Nutrition 0.000 claims abstract description 16
- 244000170916 Paeonia officinalis Species 0.000 claims abstract description 16
- 235000006484 Paeonia officinalis Nutrition 0.000 claims abstract description 16
- LPLVUJXQOOQHMX-QWBHMCJMSA-N glycyrrhizinic acid Chemical compound O([C@@H]1[C@@H](O)[C@H](O)[C@H](O[C@@H]1O[C@@H]1C([C@H]2[C@]([C@@H]3[C@@]([C@@]4(CC[C@@]5(C)CC[C@@](C)(C[C@H]5C4=CC3=O)C(O)=O)C)(C)CC2)(C)CC1)(C)C)C(O)=O)[C@@H]1O[C@H](C(O)=O)[C@@H](O)[C@H](O)[C@H]1O LPLVUJXQOOQHMX-QWBHMCJMSA-N 0.000 claims abstract description 12
- 235000011477 liquorice Nutrition 0.000 claims abstract description 12
- 241000382455 Angelica sinensis Species 0.000 claims abstract description 9
- 244000298479 Cichorium intybus Species 0.000 claims abstract 5
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 49
- 239000008187 granular material Substances 0.000 claims description 37
- 239000000284 extract Substances 0.000 claims description 24
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 21
- 238000002156 mixing Methods 0.000 claims description 19
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 claims description 18
- 239000000463 material Substances 0.000 claims description 18
- 238000000034 method Methods 0.000 claims description 12
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 claims description 12
- 235000002722 Dioscorea batatas Nutrition 0.000 claims description 11
- 235000006536 Dioscorea esculenta Nutrition 0.000 claims description 11
- 240000001811 Dioscorea oppositifolia Species 0.000 claims description 11
- 235000003416 Dioscorea oppositifolia Nutrition 0.000 claims description 11
- 238000002360 preparation method Methods 0.000 claims description 10
- 238000001914 filtration Methods 0.000 claims description 9
- 239000004375 Dextrin Substances 0.000 claims description 8
- 229920001353 Dextrin Polymers 0.000 claims description 8
- 235000019425 dextrin Nutrition 0.000 claims description 8
- 239000008213 purified water Substances 0.000 claims description 8
- 238000001694 spray drying Methods 0.000 claims description 8
- 108010007119 flavourzyme Proteins 0.000 claims description 7
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 claims description 6
- 230000003301 hydrolyzing effect Effects 0.000 claims description 6
- 229910000027 potassium carbonate Inorganic materials 0.000 claims description 6
- 230000001376 precipitating effect Effects 0.000 claims description 6
- 239000002994 raw material Substances 0.000 claims description 6
- 239000001509 sodium citrate Substances 0.000 claims description 6
- NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 claims description 6
- 239000000600 sorbitol Substances 0.000 claims description 6
- 229940107666 astragalus root Drugs 0.000 claims description 5
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 claims description 4
- 241001619461 Poria <basidiomycete fungus> Species 0.000 claims description 4
- 238000001816 cooling Methods 0.000 claims description 4
- 238000005469 granulation Methods 0.000 claims description 4
- 230000003179 granulation Effects 0.000 claims description 4
- 239000006228 supernatant Substances 0.000 claims description 4
- 239000009636 Huang Qi Substances 0.000 claims description 3
- 239000012530 fluid Substances 0.000 claims description 3
- 108090000790 Enzymes Proteins 0.000 claims description 2
- 102000004190 Enzymes Human genes 0.000 claims description 2
- 239000000796 flavoring agent Substances 0.000 claims description 2
- 235000019634 flavors Nutrition 0.000 claims description 2
- 235000013305 food Nutrition 0.000 claims description 2
- 208000004880 Polyuria Diseases 0.000 abstract description 7
- 230000035619 diuresis Effects 0.000 abstract description 7
- 206010030113 Oedema Diseases 0.000 abstract description 6
- 235000004879 dioscorea Nutrition 0.000 abstract description 6
- 235000001188 Peltandra virginica Nutrition 0.000 abstract description 5
- 235000002723 Dioscorea alata Nutrition 0.000 abstract description 4
- 235000005362 Dioscorea floribunda Nutrition 0.000 abstract description 4
- 235000004868 Dioscorea macrostachya Nutrition 0.000 abstract description 4
- 235000005361 Dioscorea nummularia Nutrition 0.000 abstract description 4
- 235000005360 Dioscorea spiculiflora Nutrition 0.000 abstract description 4
- 244000061520 Angelica archangelica Species 0.000 abstract description 3
- 235000007056 Dioscorea composita Nutrition 0.000 abstract description 3
- 235000009723 Dioscorea convolvulacea Nutrition 0.000 abstract description 3
- 235000001287 Guettarda speciosa Nutrition 0.000 abstract description 3
- 235000006350 Ipomoea batatas var. batatas Nutrition 0.000 abstract description 3
- 241000721047 Danaus plexippus Species 0.000 abstract description 2
- 239000002253 acid Substances 0.000 abstract description 2
- 239000002671 adjuvant Substances 0.000 abstract description 2
- 230000002950 deficient Effects 0.000 abstract description 2
- 230000005451 protein repair Effects 0.000 abstract description 2
- 241000218231 Moraceae Species 0.000 abstract 1
- 235000013350 formula milk Nutrition 0.000 abstract 1
- LEHOTFFKMJEONL-UHFFFAOYSA-N Uric Acid Chemical compound N1C(=O)NC(=O)C2=C1NC(=O)N2 LEHOTFFKMJEONL-UHFFFAOYSA-N 0.000 description 31
- TVWHNULVHGKJHS-UHFFFAOYSA-N Uric acid Natural products N1C(=O)NC(=O)C2NC(=O)NC21 TVWHNULVHGKJHS-UHFFFAOYSA-N 0.000 description 29
- 229940116269 uric acid Drugs 0.000 description 29
- 230000000694 effects Effects 0.000 description 18
- 239000008280 blood Substances 0.000 description 17
- 210000004369 blood Anatomy 0.000 description 17
- 230000000052 comparative effect Effects 0.000 description 16
- 241000723343 Cichorium Species 0.000 description 14
- 239000000725 suspension Substances 0.000 description 12
- 241000699670 Mus sp. Species 0.000 description 9
- 239000002245 particle Substances 0.000 description 9
- 238000002474 experimental method Methods 0.000 description 7
- KDCGOANMDULRCW-UHFFFAOYSA-N 7H-purine Chemical compound N1=CNC2=NC=NC2=C1 KDCGOANMDULRCW-UHFFFAOYSA-N 0.000 description 6
- 208000002193 Pain Diseases 0.000 description 6
- 230000035622 drinking Effects 0.000 description 5
- 210000003734 kidney Anatomy 0.000 description 5
- 208000024891 symptom Diseases 0.000 description 5
- IAKHMKGGTNLKSZ-INIZCTEOSA-N (S)-colchicine Chemical compound C1([C@@H](NC(C)=O)CC2)=CC(=O)C(OC)=CC=C1C1=C2C=C(OC)C(OC)=C1OC IAKHMKGGTNLKSZ-INIZCTEOSA-N 0.000 description 4
- 241000282461 Canis lupus Species 0.000 description 4
- 235000017443 Hedysarum boreale Nutrition 0.000 description 4
- 235000007858 Hedysarum occidentale Nutrition 0.000 description 4
- 241001465754 Metazoa Species 0.000 description 4
- 235000013399 edible fruits Nutrition 0.000 description 4
- 230000003203 everyday effect Effects 0.000 description 4
- 239000001947 glycyrrhiza glabra rhizome/root Substances 0.000 description 4
- 230000001939 inductive effect Effects 0.000 description 4
- 239000000047 product Substances 0.000 description 4
- 238000000605 extraction Methods 0.000 description 3
- 210000000952 spleen Anatomy 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- 238000012360 testing method Methods 0.000 description 3
- 240000004270 Colocasia esculenta var. antiquorum Species 0.000 description 2
- 239000004594 Masterbatch (MB) Substances 0.000 description 2
- 241000699666 Mus <mouse, genus> Species 0.000 description 2
- 230000005856 abnormality Effects 0.000 description 2
- 230000003213 activating effect Effects 0.000 description 2
- 239000013543 active substance Substances 0.000 description 2
- OFCNXPDARWKPPY-UHFFFAOYSA-N allopurinol Chemical compound OC1=NC=NC2=C1C=NN2 OFCNXPDARWKPPY-UHFFFAOYSA-N 0.000 description 2
- 229960003459 allopurinol Drugs 0.000 description 2
- 230000009286 beneficial effect Effects 0.000 description 2
- 229960001338 colchicine Drugs 0.000 description 2
- 230000002354 daily effect Effects 0.000 description 2
- 230000008021 deposition Effects 0.000 description 2
- 235000005911 diet Nutrition 0.000 description 2
- 230000037213 diet Effects 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 230000029142 excretion Effects 0.000 description 2
- 230000001965 increasing effect Effects 0.000 description 2
- 230000007774 longterm Effects 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- NAFSTSRULRIERK-UHFFFAOYSA-M monosodium urate Chemical compound [Na+].N1C([O-])=NC(=O)C2=C1NC(=O)N2 NAFSTSRULRIERK-UHFFFAOYSA-M 0.000 description 2
- 238000000465 moulding Methods 0.000 description 2
- 102000004196 processed proteins & peptides Human genes 0.000 description 2
- 108090000765 processed proteins & peptides Proteins 0.000 description 2
- 230000009467 reduction Effects 0.000 description 2
- 230000001105 regulatory effect Effects 0.000 description 2
- 230000001988 toxicity Effects 0.000 description 2
- 231100000419 toxicity Toxicity 0.000 description 2
- 206010067484 Adverse reaction Diseases 0.000 description 1
- 208000006820 Arthralgia Diseases 0.000 description 1
- 208000036487 Arthropathies Diseases 0.000 description 1
- SMDOOINVMJSDPS-UHFFFAOYSA-N Astragaloside Natural products C1=C(O)C(OC)=CC(C2=C(C(=O)C3=C(O)C=C(O)C=C3O2)OC2C(C(OC3C(C(O)C(O)C(CO)O3)O)C(O)C(CO)O2)O)=C1 SMDOOINVMJSDPS-UHFFFAOYSA-N 0.000 description 1
- 208000017667 Chronic Disease Diseases 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 208000012659 Joint disease Diseases 0.000 description 1
- 206010067482 No adverse event Diseases 0.000 description 1
- YKRGDOXKVOZESV-WRJNSLSBSA-N Paeoniflorin Chemical compound C([C@]12[C@H]3O[C@]4(O)C[C@](O3)([C@]1(C[C@@H]42)O[C@H]1[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O1)O)C)OC(=O)C1=CC=CC=C1 YKRGDOXKVOZESV-WRJNSLSBSA-N 0.000 description 1
- 108010064851 Plant Proteins Proteins 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 231100000215 acute (single dose) toxicity testing Toxicity 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 230000010398 acute inflammatory response Effects 0.000 description 1
- 238000011047 acute toxicity test Methods 0.000 description 1
- 230000006838 adverse reaction Effects 0.000 description 1
- 235000021120 animal protein Nutrition 0.000 description 1
- QMNWISYXSJWHRY-XWJCTJPOSA-N astragaloside Chemical compound O1[C@H](C(C)(O)C)CC[C@]1(C)[C@@H]1[C@@]2(C)CC[C@]34C[C@]4(CC[C@H](O[C@H]4[C@@H]([C@@H](O)[C@H](O)CO4)O)C4(C)C)C4[C@@H](O[C@H]4[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O4)O)CC3[C@]2(C)C[C@@H]1O QMNWISYXSJWHRY-XWJCTJPOSA-N 0.000 description 1
- WHQCHUCQKNIQEC-UHFFFAOYSA-N benzbromarone Chemical compound CCC=1OC2=CC=CC=C2C=1C(=O)C1=CC(Br)=C(O)C(Br)=C1 WHQCHUCQKNIQEC-UHFFFAOYSA-N 0.000 description 1
- 229960002529 benzbromarone Drugs 0.000 description 1
- 230000000975 bioactive effect Effects 0.000 description 1
- 230000001914 calming effect Effects 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 239000013078 crystal Substances 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 229940000406 drug candidate Drugs 0.000 description 1
- 235000018927 edible plant Nutrition 0.000 description 1
- 230000007071 enzymatic hydrolysis Effects 0.000 description 1
- 238000006047 enzymatic hydrolysis reaction Methods 0.000 description 1
- 239000003777 experimental drug Substances 0.000 description 1
- BQSJTQLCZDPROO-UHFFFAOYSA-N febuxostat Chemical compound C1=C(C#N)C(OCC(C)C)=CC=C1C1=NC(C)=C(C(O)=O)S1 BQSJTQLCZDPROO-UHFFFAOYSA-N 0.000 description 1
- 229960005101 febuxostat Drugs 0.000 description 1
- 238000000855 fermentation Methods 0.000 description 1
- 230000004151 fermentation Effects 0.000 description 1
- 239000000706 filtrate Substances 0.000 description 1
- 210000000232 gallbladder Anatomy 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 229940127022 high-dose drug Drugs 0.000 description 1
- 230000001976 improved effect Effects 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 231100000053 low toxicity Toxicity 0.000 description 1
- 208000030159 metabolic disease Diseases 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- 230000027939 micturition Effects 0.000 description 1
- 238000003305 oral gavage Methods 0.000 description 1
- 238000004806 packaging method and process Methods 0.000 description 1
- YKRGDOXKVOZESV-UHFFFAOYSA-N paeoniflorin Natural products O1C(C)(C2(CC34)OC5C(C(O)C(O)C(CO)O5)O)CC3(O)OC1C24COC(=O)C1=CC=CC=C1 YKRGDOXKVOZESV-UHFFFAOYSA-N 0.000 description 1
- 239000003973 paint Substances 0.000 description 1
- 235000021118 plant-derived protein Nutrition 0.000 description 1
- 229920001184 polypeptide Polymers 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 235000018102 proteins Nutrition 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 238000010992 reflux Methods 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 230000000717 retained effect Effects 0.000 description 1
- 235000014102 seafood Nutrition 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 238000005728 strengthening Methods 0.000 description 1
- 230000008093 supporting effect Effects 0.000 description 1
- 230000002195 synergetic effect Effects 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 229940126680 traditional chinese medicines Drugs 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- 210000005239 tubule Anatomy 0.000 description 1
- 210000002700 urine Anatomy 0.000 description 1
- 238000012795 verification Methods 0.000 description 1
- 238000003809 water extraction Methods 0.000 description 1
- 238000005303 weighing Methods 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/60—Moraceae (Mulberry family), e.g. breadfruit or fig
- A61K36/605—Morus (mulberry)
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/105—Plant extracts, their artificial duplicates or their derivatives
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/17—Amino acids, peptides or proteins
- A23L33/18—Peptides; Protein hydrolysates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/06—Fungi, e.g. yeasts
- A61K36/07—Basidiomycota, e.g. Cryptococcus
- A61K36/076—Poria
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/23—Apiaceae or Umbelliferae (Carrot family), e.g. dill, chervil, coriander or cumin
- A61K36/232—Angelica
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/28—Asteraceae or Compositae (Aster or Sunflower family), e.g. chamomile, feverfew, yarrow or echinacea
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
- A61K36/481—Astragalus (milkvetch)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
- A61K36/484—Glycyrrhiza (licorice)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/65—Paeoniaceae (Peony family), e.g. Chinese peony
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/71—Ranunculaceae (Buttercup family), e.g. larkspur, hepatica, hydrastis, columbine or goldenseal
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/894—Dioscoreaceae (Yam family)
- A61K36/8945—Dioscorea, e.g. yam, Chinese yam or water yam
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/896—Liliaceae (Lily family), e.g. daylily, plantain lily, Hyacinth or narcissus
- A61K36/8967—Lilium, e.g. tiger lily or Easter lily
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/01—Hydrolysed proteins; Derivatives thereof
- A61K38/012—Hydrolysed proteins; Derivatives thereof from animals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1611—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1617—Organic compounds, e.g. phospholipids, fats
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1617—Organic compounds, e.g. phospholipids, fats
- A61K9/1623—Sugars or sugar alcohols, e.g. lactose; Derivatives thereof; Homeopathic globules
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
- A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/33—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones
- A61K2236/331—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones using water, e.g. cold water, infusion, tea, steam distillation or decoction
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/33—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones
- A61K2236/333—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones using mixed solvents, e.g. 70% EtOH
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/39—Complex extraction schemes, e.g. fractionation or repeated extraction steps
Landscapes
- Health & Medical Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Mycology (AREA)
- Botany (AREA)
- Alternative & Traditional Medicine (AREA)
- Microbiology (AREA)
- Medical Informatics (AREA)
- Biotechnology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Nutrition Science (AREA)
- Food Science & Technology (AREA)
- Polymers & Plastics (AREA)
- Physical Education & Sports Medicine (AREA)
- Rheumatology (AREA)
- Inorganic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Zoology (AREA)
- Immunology (AREA)
- Pain & Pain Management (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
The invention relates to the technical field of traditional Chinese medicine compositions, and particularly discloses a compound mulberry and astragalus traditional Chinese medicine composition and application thereof; the compound mulberry and astragalus traditional Chinese medicine composition comprises mulberries, astragalus membranaceus, chicory, red paeony roots, lily, poria cocos, angelica sinensis, Chinese yams, liquorice and deep sea fish protein. The invention adopts a traditional Chinese medicine formula, mulberry, astragalus and chicory are used as monarch drugs, red peony root, lily and tuckahoe are used as ministerial drugs, angelica and yam are used as adjuvant drugs, deep sea fish protein repairs defective cells, and liquorice is used as a conductant drug; the medicines are combined to induce diuresis and reduce edema, dispel wind and remove acid, thereby achieving the technical purpose of preventing and treating gout and hyperuricemia.
Description
Technical Field
The invention relates to the technical field of traditional Chinese medicine component formulas, and particularly relates to a compound mulberry and astragalus membranaceus traditional Chinese medicine composition and application thereof.
Background
Gout is crystal-related arthropathy caused by monosodium urate (MSU) deposition, is directly related to hyperuricemia caused by purine metabolic disorder and/or uric acid excretion reduction, belongs to the category of metabolic rheumatism, and is the basis of gout. Hyperuricemia and hyperuricemia in urine, which results in the deposition of urate into the lumen or interstitium of the renal tubules, leading to an acute inflammatory response.
There are two main methods of treating gout, namely a medication method and a diet therapy method. In addition to the daily need of diet control for gout patients, uric acid reduction treatment is usually started after the acute stage of gout. The chemical medicines for treating gout mainly comprise colchicine, allopurinol, febuxostat, bromcoumarone and the like, but the chemical medicines are used for treating symptoms and root causes, and have large adverse reaction after long-term administration, thereby affecting health. Therefore, a medicine for treating gout and hyperuricemia with good treatment effect and less side effect is needed.
Disclosure of Invention
In order to solve the technical problems, the invention provides a compound mulberry and astragalus traditional Chinese medicine composition and application thereof. Adopts the formula of the traditional Chinese medicine components, induces diuresis to alleviate edema, dispels wind to remove acid, and achieves the technical purpose of treating gout and hyperuricemia.
According to one technical scheme, the compound mulberry and astragalus traditional Chinese medicine composition comprises the following components in parts by weight:
15-20 parts of mulberry, 15-20 parts of astragalus membranaceus, 8-15 parts of chicory, 8-15 parts of red paeony root, 8-15 parts of lily, 7-10 parts of poria cocos, 7-10 parts of angelica sinensis, 7-10 parts of Chinese yam, 5-9 parts of liquorice and 0.5-2 parts of deep sea fish protein.
Further, the paint comprises the following components in parts by weight:
16 parts of mulberry, 16 parts of astragalus membranaceus, 12 parts of chicory, 12 parts of red paeony root, 12 parts of lily, 8 parts of poria cocos, 8 parts of angelica sinensis, 8 parts of Chinese yam, 7 parts of liquorice and 1 part of deep sea fish protein.
According to the second technical scheme, the compound mulberry astragalus traditional Chinese medicine composition is used for preparing medicines or health-care foods for preventing and treating hyperuricemia and/or gout.
According to the third technical scheme, the traditional Chinese medicine granules for preventing and treating hyperuricemia and/or gout comprise the compound mulberry and astragalus mongholicus traditional Chinese medicine composition and auxiliary materials.
Further, the auxiliary materials comprise purified water, ethanol, dextrin, citric acid, sodium citrate, potassium carbonate and sorbitol.
The preparation method of the traditional Chinese medicine granules for preventing and treating hyperuricemia and/or gout comprises the following steps:
extracting mulberry, chicory and liquorice with water and precipitating with ethanol to obtain an extract I; precipitating red peony root, Chinese angelica root and astragalus root with alcohol and concentrating to obtain extract ②; extracting Poria and rhizoma Dioscoreae with water, hydrolyzing with deepened sea fish protein and flavor protein enzyme, concentrating under reduced pressure to obtain concentrated solution;
uniformly mixing the extract I, the extract II and the concentrated solution III, blending the density, adding auxiliary materials, and performing spray drying and granulation to obtain the compound mulberry and astragalus mongholicus traditional Chinese medicine granules.
Further, the method specifically comprises the following steps:
(1) mixing Mori fructus, herba Cichorii and Glycyrrhrizae radix, decocting with water for 2 times (each time for 2 hr), filtering the decoction, concentrating to obtain fluid extract, adding 2 times of ethanol, standing for 12 hr, collecting supernatant, and concentrating to obtain extract I;
(2) reflux-extracting radix Paeoniae Rubra, radix Angelicae sinensis, and radix astragali with 60% ethanol for 2 times (2 hr for each time and 1.5 hr for the second time), filtering, mixing extractive solutions, and concentrating to obtain extract (II);
(3) crushing Poria and rhizoma Dioscoreae into 50-80 mesh, mixing, adding 8 times of water, decocting for 4 hr, cooling to 50 deg.C, adding deep sea fish protein, hydrolyzing with flavourzyme at 50 deg.C for 240min, filtering, and concentrating to obtain concentrated solution;
(4) uniformly mixing the extract I, the extract II and the concentrated solution III to obtain a mixture, blending the mixture density with purified water and ethanol, mixing with auxiliary materials, spray drying and granulating to obtain the compound mulberry and astragalus mongholicus traditional Chinese medicine granules.
Further, in the step (1), the density of the clear paste at 60 ℃ is 1.15-1.25 g/mL;
the density of the concentrated solution obtained in the step (3) at 80 ℃ is 1.1-1.2 g/mL;
in the step (4), purified water and ethanol are used for adjusting the density of the mixture to be 1.08-1.12g/mL at 50 ℃.
Further, in the step (3), the adding amount of the flavourzyme is 1200-2000U/g calculated by the deep sea fish protein.
Compared with the prior art, the invention has the following beneficial effects:
the compound mulberry and astragalus traditional Chinese medicine composition mainly comprises 10 medicines of mulberry, astragalus, chicory, red paeony root, lily, tuckahoe, angelica, yam, liquorice and deep sea fish protein; wherein the mulberry has the effects of securing essence and reducing urination, tonifying kidney and supporting yang, the astragalus root has the effects of inducing diuresis and reducing edema, activating stagnancy and relieving arthralgia, and the chicory has the effects of clearing liver and benefiting gallbladder, and inducing diuresis and reducing edema to form a monarch drug. The red peony root has the functions of clearing heat and cooling blood, and removing blood stasis and relieving pain, the plant colchicine contained in the lily is beneficial to purine excretion, and the tuckahoe has the functions of promoting diuresis and eliminating dampness, and strengthening spleen and calming heart, and is a ministerial medicine. The angelica sinensis has the functions of enriching blood and activating blood, and the Chinese yam has the functions of tonifying spleen and nourishing stomach, tonifying kidney and arresting seminal emission, and is an adjuvant drug. The deep-sea fish protein repairs defective cells, and the liquorice clears away heat and toxic materials and coordinates the effects of the medicines as guiding medicines. The product changes the traditional method of treating the symptoms by simply removing purine, the comprehensive curative effect of the product on the basis of the origin and the origin of the product can generate profound influence on the treatment of the gout diseases with increasing incidence day by day, and the combination of the medicines has the effects of clearing heat and removing toxicity, inducing diuresis to reduce edema, nourishing yin and tonifying kidney, and particularly has good effect on the gout caused by high uric acid.
The traditional Chinese medicine composition mainly utilizes medicine-food dual-purpose traditional Chinese medicines for regulating and regulating spleen and kidney, has the effects of clearing heat and removing toxicity, inducing diuresis for removing edema, nourishing yin and tonifying kidney, can effectively prevent recurrence of gout, and the medicinal materials used in the prescription are basically medicinal and edible plant medicines, wherein the Chinese yam and the poria cocos are extracted by biological fermentation, are rich in small molecular protein peptides, have good synergistic effect on the transfer of active substances of the traditional Chinese medicine, greatly improve the bioavailability and the curative effect of the traditional Chinese medicine, have no adverse reaction after long-term administration, can treat both principal and secondary aspects of diseases, and have high clinical significance on chronic disease treatment and traditional Chinese medicine conversion innovation.
The invention also provides a preparation method of the traditional Chinese medicine particles for preventing and treating hyperuricemia and/or gout, which comprises 10 medicines of mulberry, astragalus, chicory, red paeony root, lily, tuckahoe, angelica, yam, liquorice and deep sea fish protein, wherein the extraction process of the medicinal materials adopts an alcohol extraction method aiming at different active ingredients of different medicinal components, and active substances of astragaloside in the astragalus and paeoniflorin in the red paeony root are fat-soluble; the yam and the tuckahoe contain high-quality plant protein, the deep sea fish protein is high-quality animal protein, and the deep sea fish protein is hydrolyzed by flavourzyme to prepare bioactive polypeptide which has the functions of transferring effective substances in the traditional Chinese medicine and repairing damaged cells; extracting effective components from other medicinal materials with water, precipitating with ethanol, separating, purifying, mixing, and making into preparation, wherein effective components are retained to the maximum extent during preparation process, and the therapeutic effect of the Chinese medicinal granule is improved. The preparation adopts granules, the preparation auxiliary materials comprise purified water, ethanol, dextrin, citric acid, sodium citrate, potassium carbonate and sorbitol, and the product is easy to mix by adopting a spray drying granulation preparation process.
Detailed Description
Reference will now be made in detail to various exemplary embodiments of the invention, the detailed description should not be construed as limiting the invention but as a more detailed description of certain aspects, features and embodiments of the invention.
It is to be understood that the terminology used herein is for the purpose of describing particular embodiments only and is not intended to be limiting of the invention. Further, for numerical ranges in this disclosure, it is understood that each intervening value, between the upper and lower limit of that range, is also specifically disclosed. Every smaller range between any stated value or intervening value in a stated range and any other stated or intervening value in a stated range is encompassed within the invention. The upper and lower limits of these smaller ranges may independently be included or excluded in the range.
Unless defined otherwise, all technical and scientific terms used herein have the same meaning as commonly understood by one of ordinary skill in the art to which this invention belongs. Although only preferred methods and materials are described herein, any methods and materials similar or equivalent to those described herein can be used in the practice or testing of the present invention. All documents mentioned in this specification are incorporated by reference herein for the purpose of disclosing and describing the methods and/or materials associated with the documents. In case of conflict with any incorporated document, the present specification will control.
It will be apparent to those skilled in the art that various modifications and variations can be made in the specific embodiments of the present disclosure without departing from the scope or spirit of the disclosure. Other embodiments will be apparent to those skilled in the art from consideration of the specification. The specification and examples are exemplary only.
As used herein, the terms "comprising," "including," "having," "containing," and the like are open-ended terms that mean including, but not limited to.
Example 1
(1) Weighing the raw materials according to the table 1;
TABLE 1
| Mulberry fruit | 1600g | Poria cocos (Schw.) wolf | 800g |
| Astragalus membranaceus | 1600g | Radix Angelicae sinensis | 800g |
| Chicory | 1200g | Chinese yam | 800g |
| Radix Paeoniae Rubra | 1200g | Licorice root, radix Glycyrrhizae | 700g |
| Lily bulb | 1200g | Deep sea fish protein | 100g |
Auxiliary materials: proper amount of ethanol and water, 150g of dextrin, 50g of citric acid, 50g of sodium citrate, 50g of potassium carbonate and 100g of sorbitol;
(2) extracting with water and precipitating with ethanol, mixing Mori fructus, herba Cichorii and Glycyrrhrizae radix, decocting with water for 2 times (each time for 2 hr), filtering decoction, concentrating to obtain fluid extract with relative density of 1.25(60 deg.C), adding 2 times of ethanol, standing for 12 hr, collecting supernatant, and recovering ethanol to obtain extract I;
(3) extracting radix Paeoniae Rubra, radix Angelicae sinensis, and radix astragali with 60% ethanol under reflux for 2 times (2 hr for each time and 1.5 hr for the second time), filtering, mixing extractive solutions, and recovering ethanol to obtain extract (②);
(4) biological extraction comprises crushing Poria cocos and Chinese yam to about 60 meshes, adding 8 times of water, decocting for 4 hours, cooling to 50 ℃, adding deep sea fish protein, adding flavourzyme (the addition amount is 1500U/g of the deep sea fish protein), hydrolyzing at 50 ℃, hydrolyzing for 240min, filtering, concentrating the filtrate under reduced pressure to relative density of 1.1-1.2 (80 ℃), and collecting concentrated solution (c);
(5) the granule preparation is that the extract I, the extract II and the concentrated solution III are evenly mixed, a proper amount of dextrin is added into the mixture, the density is adjusted to be 1.10(50 ℃) by purified water and ethanol, and the rest auxiliary materials of the dextrin, citric acid, sodium citrate, potassium carbonate and sorbitol are put into a spray drying granulator to be made into master batch, and spray drying granulation is carried out to obtain the traditional Chinese medicine granule. And packaging, 5 g/bag.
Comparative example 1
The difference from the embodiment 1 is that astragalus root is omitted, and the dosage of mulberry is 3200 g;
comparative example 2
The difference from the example 1 is that mulberry is omitted, and the using amount of astragalus root is 3200 g;
comparative example 3
The same as example 1, except that the lily was omitted, and the amounts of chicory and red peony root were 1800g each.
Comparative example 4
The same as example 1, except that red peony root was omitted, and chicory and lily were used in an amount of 1800g each.
Comparative example 5
The same as example 1, except that chicory was omitted and the amounts of red peony root and lily were 1800g each.
Comparative example 6
The difference from example 1 is that the addition of flavourzyme and the enzymatic hydrolysis process in step (4) are omitted.
Comparative example 7
The method is the same as the example 1 except that the step (3) and the step (4) are omitted, the raw materials including the mulberry, the astragalus membranaceus, the chicory, the red peony roots, the lily, the poria cocos, the angelica sinensis, the Chinese yams and the liquorice are uniformly mixed, the mixture is decocted for 2 times by water extraction, the decoction is filtered and concentrated to form clear paste with the relative density of 1.25(60 ℃), 2 times of ethanol is added, the mixture is kept still for 12 hours, supernatant is collected, the ethanol is recycled to form extract, deep sea fish protein is added, a proper amount of dextrin is added, the density is adjusted to be 1.10(50 ℃), and the rest of the dextrin, the citric acid, the sodium citrate, the potassium carbonate and the sorbitol are placed in a spray drying granulator to form a master batch.
Effect verification 1
1. Animal experiments
(1) Acute toxicity test in mice
About 10g of the Chinese medicinal granules prepared in example 1 is administrated by drenching (ig) mice for 1 time, namely the crude drug amount is 200g/kg/d, no animal death is found, and LD can not be detected50；
Maximum dose determination: example 1 the Chinese medicinal granule is administered continuously for 3 times within 1 day, and the total crude drug amount per day is accumulated to 500g/kg/d, and the same amount is continuously measured, and no death or abnormality of animals is observed for 7 days.
The clinical dosage of the traditional Chinese medicine granules is equivalent to 150g of crude drug per day for adults. The weight of the adult is 60kg, namely the clinical daily taking of the traditional Chinese medicine granules is equivalent to the crude drug amount of 2.5 g/kg/d. The maximum dosage of the mouse ig is equivalent to 500g/kg/d of crude drug, which is about 200 times of the dosage of clinical adult. However, the result shows that no animal death or abnormality occurs, which indicates that the traditional Chinese medicine granule of the invention has low toxicity and does not cause side effect.
(2) Mouse efficacy test
Firstly, molding: 78 mice are randomly divided into 4 groups, namely a blank control group and an experimental group, wherein the experimental group comprises a low-dose medicinal group, a medium-dose medicinal group, a high-dose medicinal group, a comparative experimental medicinal group 1-7 and a modeling group 1-2. The uric acid in the experimental group was fed at a dose of 250mg/kg/d, except for the blank control group, and was intraperitoneally injected 2 hours before blood collection on day 7 for 1 time. The blood uric acid changes of the mice are observed (the mean value of the uric acid changes of the mice in each group is taken), and the results are shown in a table 2.
TABLE 2 group blood uric acid level changes
The results show that the blood uric acid value of the mice in the uric acid group is obviously increased after the drug is taken, and the differences are statistically significant compared with the differences before the drug is taken (P < 0.01).
(II) effectiveness test
Blank control group: 0.5% CMC-Na solution.
Group of low dose administrations: 60% suspension solution of the traditional Chinese medicine granules of example 1 (12.0 g/kg/d).
The medicine group with traditional Chinese medicine dosage comprises: 120% suspension solution of the traditional Chinese medicine granules of example 1 (24.0 g/kg/d).
Group of high dose drugs: 240% suspension of the traditional Chinese medicine granules of example 1 (48.0 g/kg/d).
Comparative experimental drug set 1: 240% suspension of the traditional Chinese medicine granules of comparative example 1 (48.0 g/kg/d).
Comparing the medicine group for experiment 2: 240% suspension of the traditional Chinese medicine granules of comparative example 2 (48.0 g/kg/d).
Comparing the medicine group for experiment 3: 240% suspension of the traditional Chinese medicine granules of comparative example 3 (48.0 g/kg/d).
Comparing the medicine group for experiment 4: 240% suspension of the traditional Chinese medicine granules of comparative example 4 (48.0 g/kg/d).
Comparing the medicine group for experiment 5: 240% suspension of the traditional Chinese medicine granules of comparative example 5 (48.0 g/kg/d).
Comparing the medicine group for experiment 6: 240% suspension of the traditional Chinese medicine granules of comparative example 6 (48.0 g/kg/d).
Drug group 7 for comparison experiments: 240% suspension of the traditional Chinese medicine granules of comparative example 7 (48.0 g/kg/d).
Make module 1: allopurinol suspension solution (40 mg/kg).
The molding set 2: benzbromarone made a suspension solution (40 mg/kg).
The administration volume: 20 ml/kg.
The administration route is as follows: oral gavage (ig).
The administration time is as follows:
uric acid levels of mice were observed 24 hours after the end of the last dose, and the results are shown in table 3;
TABLE 3 Effect of drugs on uric acid levels in mice with hyperuricemia
The results show that: when the dosage of the traditional Chinese medicine granules is 24g/kg, the traditional Chinese medicine granules can obviously reduce the uric acid level of mice.
(iii) clinical research
1. For patients with gout in 52 years old, the uric acid content is 638 mu mol/L before taking, the important particles in the embodiment 1 are taken one bag at a time, one time every day, and 7 days later, the blood uric acid is 426 mu mol/L, so that the pain sense is reduced or even disappeared, the gout is felt to be attacked, the symptoms disappear after drinking, a large amount of movement can be performed, the wine can be drunk, and the gout cannot be attacked;
2. as for a patient aged 52 years old with high uric acid, the uric acid content of the patient before taking the granules is 430 mu mol/L, the important granules in the embodiment 1 are taken one bag at a time, one time in a day, and the blood uric acid is 366 mu mol/L after 7 days;
3. in 33 years old, gout patients take 690 mu mol/L uric acid before taking, take the important particles of the embodiment 1 of the invention, one bag at a time, one time every day, 3 days later, the blood uric acid is 388 mu mol/L, the pain feeling disappears, the gout is felt to be attacked, the symptoms disappear after drinking, the seafood is eaten up to night, and the gout does not attack;
4. for a gout patient in the rest 62 years, the uric acid content is 653 [ mu ] mol/L before taking, the important particles in the embodiment 1 are taken one bag at a time, one time every day, and after 5 days, the blood uric acid is 455 [ mu ] mol/L, so that the pain is reduced or even disappeared, the gout is felt to be attacked, and the symptoms disappear after drinking;
5. when a patient aged for 28 years old and suffering from gout takes the essential particles of the embodiment 1 of the invention with 663 mu mol/L of uric acid before taking, the essential particles are taken one bag at a time, one time every day, and after 3 days, the blood uric acid is 356 mu mol/L, the pain is reduced or even disappeared, the gout phenomenon does not occur after drinking wine and moving, and the gout does not occur;
6. guo in 59 years old, high uric acid patients, before taking the uric acid content 596 mu mol/L, taking the important particles of the invention in the embodiment 1, one bag at a time, one day, 7 days later, the blood uric acid is 413 mu mol/L;
7. when the gout patients are in 56 years old, the uric acid content is 662 mu mol/L before the gout patients take the important particles in the embodiment 1 of the invention, one bag of the important particles is taken once, one time is taken once a day, and after 7 days, the blood uric acid is 473 mu mol/L, the pain feeling is obviously reduced, the gout phenomenon does not occur after drinking and exercising, and the gout attack frequency is obviously reduced.
Example 2
The same as example 1 except that the raw materials were used in the amounts shown in Table 4;
TABLE 4
| Mulberry fruit | 1500g | Poria cocos (Schw.) wolf | 700g |
| Astragalus membranaceus | 2000g | Radix Angelicae sinensis | 1000g |
| Chicory | 1000g | Chinese yam | 1000g |
| Radix Paeoniae Rubra | 1000g | Licorice root, radix Glycyrrhizae | 900g |
| Lily bulb | 800g | Deep sea fish protein | 200g |
Example 3
The same as example 1 except that the raw materials were used in the amounts shown in Table 5;
TABLE 5
| Mulberry fruit | 2000g | Poria cocos (Schw.) wolf | 1000g |
| Astragalus membranaceus | 1500g | Radix Angelicae sinensis | 700g |
| Chicory | 1500g | Chinese yam | 700g |
| Radix Paeoniae Rubra | 800g | Licorice root, radix Glycyrrhizae | 500g |
| Lily bulb | 1000g | Deep sea fish protein | 50g |
Example 4
The same as example 1 except that the raw material amounts are shown in Table 6;
TABLE 6
| Mulberry fruit | 1800g | Poria cocos (Schw.) wolf | 800g |
| Astragalus membranaceus | 1800g | Radix Angelicae sinensis | 900g |
| Chicory | 1200g | Chinese yam | 900g |
| Radix Paeoniae Rubra | 1500g | Licorice root, radix Glycyrrhizae | 800g |
| Lily bulb | 1500g | Deep sea fish protein | 100g |
The effect of the traditional Chinese medicine granules prepared in examples 2 to 4 is verified by the scheme of example 1, and the results show that the effect of reducing uric acid in blood and the effect of treating gout are similar to those of example 1, and the traditional Chinese medicine granules have excellent effects of reducing uric acid in blood and treating gout.
The above description is only for the purpose of illustrating the preferred embodiments of the present invention and is not to be construed as limiting the invention, and any modifications, equivalents and improvements made within the spirit and principle of the present invention are intended to be included therein.
Claims (9)
1. The compound mulberry and astragalus traditional Chinese medicine composition is characterized by comprising the following components in parts by mass:
15-20 parts of mulberry, 15-20 parts of astragalus membranaceus, 8-15 parts of chicory, 8-15 parts of red paeony root, 8-15 parts of lily, 7-10 parts of poria cocos, 7-10 parts of angelica sinensis, 7-10 parts of Chinese yam, 5-9 parts of liquorice and 0.5-2 parts of deep sea fish protein.
2. The compound mulberry and astragalus membranaceus traditional Chinese medicine composition as claimed in claim 1, which is characterized by comprising the following components in parts by mass:
16 parts of mulberry, 16 parts of astragalus membranaceus, 12 parts of chicory, 12 parts of red paeony root, 12 parts of lily, 8 parts of poria cocos, 8 parts of angelica sinensis, 8 parts of Chinese yam, 7 parts of liquorice and 1 part of deep sea fish protein.
3. The application of the compound mulberry astragalus mongholicus traditional Chinese medicine composition according to any one of claims 1-2, wherein the compound mulberry astragalus mongholicus traditional Chinese medicine composition is used for preparing medicines or health-care foods for preventing and treating hyperuricemia and/or gout.
4. A traditional Chinese medicine granule for preventing and treating hyperuricemia and/or gout, which is characterized in that raw materials comprise the compound mulberry astragalus traditional Chinese medicine composition as claimed in any one of claims 1 to 2 and auxiliary materials.
5. The traditional Chinese medicine granule for preventing and treating hyperuricemia and/or gout according to claim 4, wherein the auxiliary materials comprise a proper amount of purified water, a proper amount of ethanol, dextrin, citric acid, sodium citrate, potassium carbonate and sorbitol.
6. The preparation method of the traditional Chinese medicine granules for preventing and treating hyperuricemia and/or gout according to any one of claims 4 to 5, characterized by comprising the following steps:
extracting mulberry, chicory and liquorice with water and precipitating with ethanol to obtain an extract I; precipitating red peony root, Chinese angelica root and astragalus root with alcohol and concentrating to obtain extract ②; extracting Poria and rhizoma Dioscoreae with water, hydrolyzing with deepened sea fish protein and flavor protein enzyme, concentrating under reduced pressure to obtain concentrated solution;
uniformly mixing the extract I, the extract II and the concentrated solution III, blending the density, adding auxiliary materials, and performing spray drying and granulation to obtain the compound mulberry and astragalus mongholicus traditional Chinese medicine granules.
7. The preparation method of the traditional Chinese medicine granules for preventing and treating hyperuricemia and/or gout as claimed in claim 6, which specifically comprises the following steps:
(1) mixing Mori fructus, herba Cichorii and Glycyrrhrizae radix, decocting with water for 2 times (each time for 2 hr), filtering the decoction, concentrating to obtain fluid extract, adding 2 times of ethanol, standing for 12 hr, collecting supernatant, and concentrating to obtain extract I;
(2) reflux-extracting radix Paeoniae Rubra, radix Angelicae sinensis, and radix astragali with 60% ethanol for 2 times (2 hr for each time and 1.5 hr for the second time), filtering, mixing extractive solutions, and concentrating to obtain extract (II);
(3) crushing Poria and rhizoma Dioscoreae into 50-80 mesh, mixing, adding 8 times of water, decocting for 4 hr, cooling to 50 deg.C, adding deep sea fish protein, hydrolyzing with flavourzyme at 50 deg.C for 240min, filtering, and concentrating to obtain concentrated solution;
(4) uniformly mixing the extract I, the extract II and the concentrated solution III to obtain a mixture, blending the mixture density with purified water and ethanol, mixing with auxiliary materials, spray drying and granulating to obtain the compound mulberry and astragalus mongholicus traditional Chinese medicine granules.
8. The method for preparing traditional Chinese medicine granules for preventing and treating hyperuricemia and/or gout as claimed in claim 7, wherein in the step (1), the density of the clear paste at 60 ℃ is 1.15-1.25 g/mL;
the density of the concentrated solution obtained in the step (3) at 80 ℃ is 1.1-1.2 g/mL; in the step (4), purified water and ethanol are used for adjusting the density of the mixture to be 1.08-1.12g/mL at 50 ℃.
9. The method for preparing traditional Chinese medicine granules for preventing and treating hyperuricemia and/or gout as claimed in claim 7, wherein in the step (3), the addition amount of flavourzyme is 1200-2000U/g calculated by deep sea fish protein.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202110249323.4A CN112826917A (en) | 2021-03-08 | 2021-03-08 | Compound mulberry and astragalus traditional Chinese medicine composition and application thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202110249323.4A CN112826917A (en) | 2021-03-08 | 2021-03-08 | Compound mulberry and astragalus traditional Chinese medicine composition and application thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN112826917A true CN112826917A (en) | 2021-05-25 |
Family
ID=75929676
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202110249323.4A Pending CN112826917A (en) | 2021-03-08 | 2021-03-08 | Compound mulberry and astragalus traditional Chinese medicine composition and application thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN112826917A (en) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN115843905A (en) * | 2022-11-30 | 2023-03-28 | 党乐飞 | Tea drink for treating gout |
Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN108210791A (en) * | 2018-03-31 | 2018-06-29 | 张珈荣 | For treating the Chinese medicine of gout and preparation method |
| CN108837121A (en) * | 2018-09-02 | 2018-11-20 | 刘德平 | A kind of Chinese medicine composition and preparation method thereof for treating high lithemia |
| WO2019127036A1 (en) * | 2017-12-26 | 2019-07-04 | 刘继勇 | Traditional chinese medicine composition for preventing and treating lithiasis, hyperuricemia, gout and complications thereof, preparation method therefor, and application thereof |
| CN110960612A (en) * | 2018-09-29 | 2020-04-07 | 张立山 | Traditional Chinese medicine composition for preventing and treating gout |
| CN111110825A (en) * | 2019-12-30 | 2020-05-08 | 云南中科本草科技有限公司 | Composition for reducing uric acid and preparation method and application thereof |
-
2021
- 2021-03-08 CN CN202110249323.4A patent/CN112826917A/en active Pending
Patent Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2019127036A1 (en) * | 2017-12-26 | 2019-07-04 | 刘继勇 | Traditional chinese medicine composition for preventing and treating lithiasis, hyperuricemia, gout and complications thereof, preparation method therefor, and application thereof |
| CN108210791A (en) * | 2018-03-31 | 2018-06-29 | 张珈荣 | For treating the Chinese medicine of gout and preparation method |
| CN108837121A (en) * | 2018-09-02 | 2018-11-20 | 刘德平 | A kind of Chinese medicine composition and preparation method thereof for treating high lithemia |
| CN110960612A (en) * | 2018-09-29 | 2020-04-07 | 张立山 | Traditional Chinese medicine composition for preventing and treating gout |
| CN111110825A (en) * | 2019-12-30 | 2020-05-08 | 云南中科本草科技有限公司 | Composition for reducing uric acid and preparation method and application thereof |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN115843905A (en) * | 2022-11-30 | 2023-03-28 | 党乐飞 | Tea drink for treating gout |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN110559403B (en) | Traditional Chinese medicine composition for preventing and treating hyperuricemia and preparation method and application thereof | |
| CN104435749A (en) | Dendrobium officinale compound preparation as well as preparation method and application of dendrobium officinale compound preparation | |
| CN102397372A (en) | Medicinal composition and pharmaceutical preparation and application thereof to treating irritable bowel syndrome | |
| CN112826917A (en) | Compound mulberry and astragalus traditional Chinese medicine composition and application thereof | |
| CN102078600B (en) | Anti-cancer compound ganoderma composition, application thereof and pharmaceutical composition containing same | |
| CN102940747B (en) | Medicine composition for treating gout | |
| CN110215485A (en) | Chinese medicine composition and preparation method thereof for treating diabetes skin ulcer | |
| CN1261151C (en) | Medicine for treating acute cholecystitis and chronic cholecystitis and its preparing method | |
| CN1237998C (en) | Effervescence tablet for treating children's cough and asthma and its preparation | |
| CN1111064C (en) | Hepatitis treating medicine and its production process | |
| CN115364179B (en) | Traditional Chinese medicine composition for reducing blood uric acid as well as preparation method and application thereof | |
| CN114191532B (en) | Uric acid reducing composition, preparation method and application thereof | |
| CN115607587B (en) | Application of Aidi preparation in preparation of medicament for treating herpes zoster | |
| CN108815360B (en) | A Chinese medicinal composition for treating infantile acute tonsillitis and acute pharyngitis, and its preparation method | |
| CN102631486B (en) | Health care composition | |
| CN109771480B (en) | Traditional Chinese medicine composition for treating livestock and poultry hepatotoxicity and preparation method and preparation thereof | |
| CN108653554B (en) | A Chinese medicinal composition for treating respiratory system diseases, and its preparation method | |
| CN100482264C (en) | Shenling Chinese medicine preparation for strengthening body resistance | |
| CN106692698B (en) | Bletilla striata cough relieving granule and preparation method thereof | |
| CN1204916C (en) | Medicine for treating depression and its preparation method | |
| CN1488385A (en) | Chinese medicine composition for treating climacteric metancholia for women and preparing method thereof | |
| CN104524359A (en) | Traditional Chinese medicine composition and preparing method and application thereof | |
| CN1189207C (en) | Chinese medicinal composition for improving human immunity and its preparation method | |
| CN105055818A (en) | Pharmaceutical preparation for treating neurodermatitis | |
| CN105770188B (en) | liver-protecting traditional Chinese medicine preparation and preparation method thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| RJ01 | Rejection of invention patent application after publication |
Application publication date: 20210525 |
|
| RJ01 | Rejection of invention patent application after publication |